* Asterias biotherapeutics receives FDA clearance to enroll C-4 patients in Scistar study

* Says amendment expands eligibility criteria to include patients with a C-4 spinal cord injury

* Asterias biotherapeutics inc - ‍FDA accepted co's amendment to clinical research protocol for its ongoing AST-OPC1 scistar phase 1/2A clinical trial​

* Says amendment extends dosing window from 14 to 30 days to 21 to 42 days post-injury

* Asterias Biotherapeutics Inc - ‍amendment expands eligibility criteria to include patients with a C-4 spinal cord injury Source text for Eikon: Further company coverage: